Chardan Capital Raises PT on 4D Molecular to $25.

Chardan Capital Raises PT on 4D Molecular to $25.

In a recent development, Chardan Capital has raised its price target on 4D Molecular Therapeutics (FDMT) to $25, reflecting optimism in the company's growth prospects. This move comes after the biopharmaceutical company reported positive 60-week results from its 4D-150 SPECTRA clinical trial for diabetic macular edema (DME) [1]. The company's 4D-150 treatment demonstrated durable and dose-dependent clinical activity, leading to sustained improvements in visual acuity and anatomical control.

Chardan Capital's revised target underscores the potential of 4D Molecular's pipeline, which includes multiple genetic medicine product candidates in various therapeutic areas, such as ophthalmology, cardiology, and pulmonology. The company's product pipeline includes 4D-150, which is in phase 1/2 clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema [2].

Goldman Sachs has also maintained a Buy rating on 4D Molecular, with a price target of $38.00, after the company's second-quarter earnings report. The investment bank noted that the company's strategic prioritization and workforce reduction will extend its cash runway into 2028, offsetting increased R&D expenses from the wet AMD trials [1].

Despite the positive developments, market concerns about competition from aflibercept biosimilars for 4D Molecular's ophthalmology programs persist. However, the company's recent clinical trial results and the positive outlook from major financial institutions suggest that investors remain optimistic about its long-term prospects.

References:
[1] https://www.investing.com/news/analyst-ratings/4d-molecular-therapeutics-stock-maintains-buy-rating-at-goldman-sachs-93CH-4183469
[2] https://www.marketbeat.com/stocks/NASDAQ/FDMT/